Clinical trial
Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety…
NCT00219349 · New York State Psychiatric Institute, Other · Completed
Key facts
| NCT number | NCT00219349 |
|---|---|
| Title | Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD) |
| Official title | Cognitive-Behavioral Therapy and Pharmacotherapy Augmentation for Generalized Anxiety Disorder: A Pilot Investigation |
| Lead sponsor | New York State Psychiatric Institute, Other |
| Collaborators | Forest Laboratories Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Generalized Anxiety Disorder |
| Intervention type | Behavioral, Drug |
| Interventions | Cognitive Behavioral Therapy, escitalopram |
| Enrollment | 25 |
| Start date | Jan 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 19, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: